{"nctId":"NCT00975000","briefTitle":"Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients","startDateStruct":{"date":"2009-12-03","type":"ACTUAL"},"conditions":["Chronic Allograft Nephropathy","Chronic Kidney Disease","Chronic Renal Failure","Disordered Mineral Metabolism","End Stage Renal Disease","Hyperparathyroidism","Hypophosphatemia","Kidney Disease","Kidney Transplantation","Post Renal Transplantation"],"count":114,"armGroups":[{"label":"Cinacalcet","type":"EXPERIMENTAL","interventionNames":["Drug: Cinacalcet"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cinacalcet","otherNames":["Mimpara","Sensipar"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Received a kidney transplant ≥ 9 weeks at time of Screening and ≤ 24 months before first dose\n* May be the first kidney transplant or a repeat kidney transplant.\n* Subjects with a functional, stable kidney transplant, defined as MDRD estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² (chromic kidney disease stage 3 or better) at Screening.\n* Men or women ≥ 18 years at the start of Screening (ie, time of informed consent).\n* Corrected total serum calcium \\> 10.5 mg/dL (2.63 mmol/L), defined as the mean of 2 values in Screening period.\n* iPTH \\> 100 pg/mL (10.6 pmol/L), during the Screening period (obtained at either Screen 1 or Screen 2).\n\nExclusion Criteria:\n\n* Received cinacalcet therapy post-transplant for more than 14 days cumulatively post-transplant. If cinacalcet therapy was received for a total of 14 days or less post-transplant, there must be a 4-week washout before subject is eligible for screening (Note: This does not exclude pre-transplant use of cinacalcet).\n* Anticipated parathyroidectomy within 6 to12 months after Randomization.\n* Ongoing therapy with bisphosphonates or use within 6 months prior to Screening.\n* Ongoing use of 1,25-dihydroxyvitamin D3 (including other active vitamin D metabolites or analogues) or use within 30 days prior to Screening.\n* Ongoing use of calcium supplements or use within 30 days prior to Screening.\n* Ongoing use of phosphate binders (calcium or non-calcium containing) or use within 30 days prior to Screening.\n* Ongoing use of a thiazide diuretic.\n* Subjects with a history of seizures who had a seizure within the 3 months prior to Randomization, which required adjustments to the seizure medication.\n* Acute Kidney Injury (AKI) or renal biopsy within 6 weeks prior to Screening, unless it is an institutional protocol-driven biopsy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"78.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 52 in Bone Mineral Density at the Femoral Neck","description":"Bone mineral density (BMD) was measured using dual X-ray absorptiometry (DXA).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the EAP in Mean Serum Phosphorus","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.48"},{"groupId":"OG001","value":"0.52","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in eGFR","description":"eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"8.70"},{"groupId":"OG001","value":"-0.37","spread":"11.69"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the EAP in Corrected Total Calcium","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.51"},{"groupId":"OG001","value":"-1.53","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the EAP in Intact Parathyroid Hormone (iPTH)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"106.4"},{"groupId":"OG001","value":"-127.9","spread":"254.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the EAP in Urine Phosphorus","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"31.51"},{"groupId":"OG001","value":"-2.62","spread":"43.93"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Parathyroidectomy","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Parathyroidectomy","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":57},"commonTop":["Nasopharyngitis","Oedema peripheral","Urinary tract infection","Nausea","Fatigue"]}}}